Skip to main content
Clinical Trials/NCT06537024
NCT06537024
Completed
Not Applicable

Replication Study to Analyze the Surgical Treatment of Proximal Humeral Fracture

University Hospital Muenster0 sites32,953 target enrollmentJanuary 1, 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Proximal Humeral Fracture
Sponsor
University Hospital Muenster
Enrollment
32953
Primary Endpoint
Surgical complications during index case
Status
Completed
Last Updated
last year

Overview

Brief Summary

The study at hand aimed to analyze the replicability of the observed treatment effects in these studies published by Koeppe et al. and Stolberg-Stolberg et al.

Detailed Description

see Protocol

Registry
clinicaltrials.gov
Start Date
January 1, 2011
End Date
December 31, 2022
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
University Hospital Muenster
Responsible Party
Principal Investigator
Principal Investigator

Prof. Dr. med. J. Christoph Katthagen

Senior Consultant

University Hospital Muenster

Eligibility Criteria

Inclusion Criteria

  • all patients will be included, who had an inpatient coded treatment using LPF or RTSA

Exclusion Criteria

  • Incomplete insurance status within two years before index
  • Incomplete basic information
  • Age\<65 years
  • Missing diagnosis of PHF (ICD: S42.2) within two years before surgery
  • Previous surgical treatment (RTSA, LPF or other fracture fixation)
  • Coded polytrauma
  • Bone tumors/ bone metastasis
  • Both sides or missing information of surgery side
  • COVID-19 infection during index hospitalization

Outcomes

Primary Outcomes

Surgical complications during index case

Time Frame: through hospital stay, an average of 16 days

See above, only events during hospitalization

30-day mortality

Time Frame: 30 days

Death from any cause during the first 30-days after surgery.

Overall survival (OS)

Time Frame: up to 12 years

Time from discharge of index hospitalization to death of any case.

Major adverse events during index case

Time Frame: through hospital stay, an average of 16 days

See above, only events during hospitalization

Major adverse events after discharge

Time Frame: up to 12 years

Time from discharge of index hospitalization to MAE as defined above

Thromboembolic events during index

Time Frame: through hospital stay, an average of 16 days

See above, only events during hospitalization

Thromboembolic events (or death) after discharge

Time Frame: up to 12 years

Time from discharge of index hospitalization to a thromboembolic event or death of any case.

Surgical complications after discharge

Time Frame: up to 12 years

Time from discharge of index hospitalization to surgical complications, with death being considered as a competing risk event.

Secondary Outcomes

  • Implant-associated complication during index(through hospital stay, an average of 16 days)
  • Non-Implant-associated complication during index(through hospital stay, an average of 16 days)
  • Minor outpatient complications after discharge(up to 12 years)

Similar Trials